Wilbanks Smith & Thomas Asset Management’s Citius Pharmaceuticals CTXR Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,963	Closed	-$76K	–	511
2021 Q4	$76K	Hold	1,963	–	–	﹤0.01%	506
2021 Q3	$100K	Buy	1,963 +72	+4%	+$3.61K	﹤0.01%	495
2021 Q2	$164K	Buy	1,891 +1,091	+136%	+$65.6K	0.01%	476
2021 Q1	$36K	Hold	800	–	–	﹤0.01%	468
2020 Q4	$20K	Hold	800	–	–	﹤0.01%	435
2020 Q3	$21K	Buy	+800	New	+$22.6K	﹤0.01%	390

Other funds holding CTXR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's CTXR Position: Q1 2022 in Review

Wilbanks Smith & Thomas Asset Management sold out of Citius Pharmaceuticals (CTXR) in Q1 2022, closing a stake of 1,963 shares — an estimated $76K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in CTXR in Q3 2020 and held it in 6 quarters. The position peaked at $164K in Q2 2021. 76 funds tracked by Wall St. Rank hold CTXR as of Q1 2022.

Wilbanks Smith & Thomas Asset Management reported no remaining Citius Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Wilbanks Smith & Thomas Asset Management sold 1,963 Citius Pharmaceuticals shares in Q1 2022, an estimated $76K.
Wilbanks Smith & Thomas Asset Management first reported a position in Citius Pharmaceuticals in Q3 2020 and held it in 6 quarters.
Wilbanks Smith & Thomas Asset Management's Citius Pharmaceuticals position peaked at $164K in Q2 2021.
76 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2022.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q1 2022, filed 5 May 2022.